MitoQ is unique Otago patent · conventional CoQ10 ubiquinol remains valid option for non-mitochondrial-targeted indications.
Mitoquinol mesylate + TPP+
Best for
Ideal use: preventive endothelium, emerging Parkinson, pro endurance athletics, neuroprotection.
Advantages
Unique patented form · sole mitochondrial-targeted evidence (1,000x IMM accumulation). RCT pedigree (Rossman, Williamson, Snow). No equivalent alternatives.
Disadvantages
Expensive (~50-80 €/month at 20 mg). Limited availability · mainly direct from MitoQ Ltd NZ. Limited RCTs in some long-term endpoints.
Reduced ubiquinol (Kaneka Q+®)
Best for
Ideal use: general CoQ10 indications (statins, mito fatigue, conventional cardio). NOT mitochondrial-targeted.
Advantages
Economical (~25-45 €/month). Decades of evidence. General mitochondrial fatigue + statins + cardio indications. Many RCTs.
Disadvantages
Only <10% reaches mitochondria · not real mitochondrial-targeted. For Rossman-like endothelial effect: MitoQ superior.
Ideal use: preventive endothelium, emerging Parkinson, pro endurance athletics, neuroprotection.
Ideal use: general CoQ10 indications (statins, mito fatigue, conventional cardio). NOT mitochondrial-targeted.
MitoQ is unique Otago patent · conventional CoQ10 ubiquinol remains valid option for non-mitochondrial-targeted indications.